Sodium-glucose Co-transporter 2 (SGLT2) inhibitor dapagliflozin acutely activates cardiomyocyte HIF-1α signaling via succinate, a signaling metabolite.
Sato T, Isagawa T, Sugiura Y, Sawaki D, Nakagama Y, Kuchimaru T, Minatsuki S, Sato S, Ono K, Chuluun-Erdene A, Semba H, Ito M, Kawakami T, Tanaka R, Sakamoto M, Asagiri M, Harada H, Stockmann C, Yonezawa T, Hirota Y, Kido Y, Otsu K, Kohro T, Manabe I, Komuro I, Takeda N.
Sato T, et al. Among authors: takeda n.
J Pharmacol Sci. 2026 Apr;160(4):221-231. doi: 10.1016/j.jphs.2026.01.008. Epub 2026 Feb 4.
J Pharmacol Sci. 2026.
PMID: 41795960
Free article.